The development of extended-release dosage forms with adequate drug release is a challenge for pharmaceutical companies, mainly when the drug presents high solubility, as in Biopharmaceutics Classification System (BCS) class I. This study aimed to develop extended-release mini-tablets containing metoprolol succinate (MS), while integrating design of experiments (DOE) and physiologically based biopharmaceutics modeling (PBBM), to predict its absorption and to run virtual bioequivalence (VBE) studies in both fasted and fed states. Core mini-tablet formulations (F1, F2, and F3) were prepared by direct compression and coated using nine coating formulations planned using DOE, while varying the percentages of the controlled-release and the pore-forming polymers. The coated mini-tablets were submitted to a dissolution test; additional formulations were prepared that were optimized by simulating the dissolution profiles, and the best one was submitted to VBE studies using GastroPlus® software. An optimized formulation (FO) containing a mixture of immediate and extended-release mini-tablets showed to be bioequivalent to the reference drug product containing MS when running VBE studies in both fasted and fed states. The integration of DOE and PBBM showed to be an interesting approach in the development of extended-release mini-tablet formulation containing MS, and can be used to rationalize the development of dosage forms.
The aim of this study was to use the physiologically based biopharmaceutics modeling (PBBM) strategy to evaluate the biopredictive power of different dissolution test conditions for immediate release tablets containing 20 mg of rivaroxaban. The model was developed and validated with literature data and used to predict plasma concentration-time curves of reference drug product Xarelto® 20 mg based on the experimental dissolution profiles. Virtual bioequivalence studies were run considering each dissolution profile under fasted and fed conditions to evaluate the biopredictive power of each dissolution method. The dissolution profiles and the results of the virtual bioequivalence studies showed that it is necessary to have a minimal amount of surfactant (0.15%), rotation speed of at least 60 rpm and 900 mL of acetate buffer solution pH 4.5 to achieve biopredictive condition. Using the PBBM approach, it was possible to evaluate the differences of the dissolution test conditions, and its influence on drug bioavailability, setting up a dissolution specification for rivaroxaban immediate release tablets.